Many of the vaccines critically needed to fight the world's most prevalent infectious diseases are not likely to be developed. A financial modeling study of 538 candidate products for 35 neglected diseases estimated the costs and likelihood that each would progress to a product launch. Using a new tool known as Portfolio-to-Impact (P2I), the researchers found only 128 of those candidates would make it through the drug development pipeline.